[Therapeutic indications of Cortalugel 20 in hepatic and gastro-enterological diseases (author's transl)].
Regular observation of 40 patients treated with Cortalugel 20 confirmed that the association of aluminum phosphate with prednisolone produced no phenomenon of chelation and did not affect absorption of the latter compound. The product was well-tolerated by the digestive system during prolonged administration for the treatment of hepatic and gastro-enterological diseases for which corticotherapy is usually administered.
D000535:Aluminum / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D006505:Hepatitis / Q000188:drug therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy; D008107:Liver Diseases / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage*
D004338:Drug Combinations; D011239:Prednisolone; D000535:Aluminum
Utilisation thérapeutique du Cortalugel 20 dans un service d'hépato-gastro-entérologie.